title: Cancer Cytogenetics
author:  Sverre Heim 
description: Cancer Cytogenetics<br /> <br /> Second Edition<br /> <br /> Sverre Heim<br /> <br /> Felix Mitelman<br /> <br /> Over the past decade, cancer cytogenetics has become widely recognized both as a basic research tool for investigations of tumor biology and a clinical methodology providing vital insights into cancer development and progression. The first edition of this book presented a much-needed conceptual synthesis of this new and rapidly moving field. Now, Cancer Cytogenetics, Second Edition offers a comprehensive, expanded, and up-to-date summary of recent dramatic advances in this area, incorporating a vast amount of new data from the latest basic and clinical investigations.<br /> <br /> Written by two leading experts, Cancer Cytogenetics, Second Edition provides an authoritative description of neoplastic processes at the chromosomal level of genomic organization. The book opens with a summary of cytogenetic methods and terminology, then reviews the key aspects of chromosomal abnormalities in cancer. The remainder of the book is devoted to the karyotypic and molecular genetic characteristics of specific neoplastic disorders and their clinical implications. Included in these sections are eleven entirely new chapters focusing on different types of non-hematologic neoplasms. This extensive expansion from the single-chapter coverage of the first edition was necessitated by a veritable explosion of knowledge in the field of solid tumor cytogenetics.<br /> <br /> Specific topics in the Second Edition include:<br /> * Acute and chronic myeloproliferative disorders<br /> * Myelodysplastic syndromes<br /> * Acute and chronic lymphoproliferative disorders<br /> * Malignant lymphomas<br /> * Solid tumors of the respiratory, digestive, and urinary tracts; breast, genital, endocrine, and nervous systems; eye, skin, and bone; and soft tissue<br /> <br /> This Second Edition of Cancer Cytogenetics is a valuable resource for researchers in a wide range of fields, including cytogenetics, medical and molecular genetics, cellular and molecular biology, oncology, and hematology. With its complete coverage of the cytogenetic mechanisms underlying neoplasia, this text will also be an indispensable reference for all clinicians involved in the diagnosis and treatment of cancer patients.
zlib_text: AZACITIDINE
  CAS No. 320-67-2 
  First Listed in the Eighth Report on Carcinogens 
  NH2
  N
  N
  HO
  O
  H
  H
  H
  H
  N
  O
  OH
  OH
  CARCINOGENICITY
  Azacitidine (5-Azacytidine; 5-AzaC) is reasonably anticipated to be a human carcinogen
  based on evidence of malignant tumor formation at multiple tissue sites in multiple species of
  experimental animals (NCI 1978, Luz and Murray 1988, IARC 1990). 
  5-AzaC, when administered by intraperitoneal (i.p.) injection, induced lymphoreticular
  neoplasms and skin and lung tumors in male and/or female mice (NCI 1978, Luz and Murray
  1988, IARC 1990), and leukemia, lymphoma, and tumors of the liver and lung in offspring of 
  treated pregnant dams (IARC 1990). In male rats, 5-AzaC administered i.p. induced squamous 
  cell carcinoma of the skin and interstitial-cell tumors of the testes, and appeared to increase the
  incidence of non-testis tumors in male offspring of treated dams (IARC 1990). 
  No data were available to evaluate the carcinogenicity of 5-AzaC in humans (IARC
  1990).